发明申请
- 专利标题： SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS
- 专利标题（中）： 可溶性IL-17RA / RC融合蛋白及相关方法
-
申请号： US12828041申请日： 2010-06-30
-
公开(公告)号： US20110014656A1公开(公告)日： 2011-01-20
- 发明人: STEVEN D. LEVIN , MARK W. RIXON , GAO ZEREN
- 申请人： STEVEN D. LEVIN , MARK W. RIXON , GAO ZEREN
- 申请人地址： US WA SEATTLE
- 专利权人： ZYMOGENETICS, INC.
- 当前专利权人： ZYMOGENETICS, INC.
- 当前专利权人地址： US WA SEATTLE
- 主分类号： C12P21/02
- IPC分类号： C12P21/02 ; C07H21/04 ; C12N15/63 ; C12N5/10
摘要：
Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
公开/授权文献
- US08084231B2 Soluble IL-17RA/RC fusion proteins and related methods 公开/授权日：2011-12-27